悦心健康（002162.SZ）2月27日在投资者互动平台表示，近五年（2020年—2024年）来，公司大健康业 务的营业收入占总营业收入的比重未达10%，根据年报编制要求，无需披露该板块业务的成本及毛利率 等数据。 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司近5年来大健康业务的财务数据可以在哪里 得到？ （文章来源：每日经济新闻） ...

Group 1 - The company Yueshen Health expects a net profit attributable to shareholders of 7.5 million to 11 million yuan for 2025, representing a year-on-year growth of 105.10% to 107.48% [1] - The main reason for the performance change is a 15.5% increase in revenue from the health business compared to the previous year [1] - The company anticipates a reduction of approximately 78.76 million yuan in various asset impairment losses compared to the previous year [1] Group 2 - The company's tile business experienced a 6% year-on-year decline in sales volume and a 15.7% decrease in sales revenue due to intensified market competition [1] - As a result of the decline in tile business revenue, the company expects a reduction of approximately 41 million yuan in four expense categories compared to the previous year [1] - The company also projects a decrease of approximately 33.89 million yuan in income tax expenses compared to the previous year [1]

Group 1 - The core point of the article is the resignation of Mr. Li Xianlin from his position as Vice President of China National Pharmaceutical Group Modern (国药现代) due to reaching retirement age, and he will not hold any positions in the company or its subsidiaries after his departure [2]. Group 2 - For the fiscal year 2024, the revenue composition of China National Pharmaceutical Group Modern is as follows: formulations account for 49.84%, intermediates and active pharmaceutical ingredients account for 47.53%, other businesses account for 2.44%, and health-related businesses account for 0.19% [2].